<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>37(6)</volume><submitter>Einan-Lifshitz A</submitter><pubmed_abstract>&lt;h4>Purpose&lt;/h4>Standard corneal collagen cross-linking (S-CXL) is an effective treatment to arrest Keratoconus (KC) progression in children. Less is known on the long-term efficacy of accelerated CXL (A-CXL) in paediatric populations.&lt;h4>Methods&lt;/h4>A historical cohort analysis of paediatric patients (≤18 years) with KC who underwent S-CXL and A-CXL at two tertiary referral centres in Israel between 2010-2017. Preoperative and 3-year postoperative evaluation included changes in visual acuity (best spectacle corrected [BSCVA]) and uncorrected [UCVA]), refractive errors, and keratometric data.&lt;h4>Results&lt;/h4>Ninety-three eyes of 93 patients were analysed (A-CXL: n = 39; S-CXL: n = 54). Baseline characteristics were similar between groups. Both groups showed a significant improvement in visual acuity compared to baseline (S-CXL: 0.810-0.602 LogMAR UCVA; A-CXL: 0.890-0.306 LogMAR UCVA, p &lt; 0.05 for both). Improvement in BSCVA and UCVA following A-CXL was non-inferior to S-CXL (&lt; ± 0.2 LogMAR). Kmax decreased by a mean of 0.98 ± 5.56 dioptres following S-CXL (p = 0.02) and by 1.48 ± 8.4 dioptres following A-CXL (p = 0.015). Thinnest pachymetry decreased following both treatments (S-CXL: by 26.8 ± 40.7 µm, p = 0.001, A-CXL: by 10.2 ± 13.4 µm, p = 0.028), the difference between groups was within the non-inferiority margin (&lt; ± 10 µm).&lt;h4>Conclusions&lt;/h4>Paediatric patients followed for three years after A-CXL showed improved visual function, reduced corneal astigmatism and Kmax, and decreased thinnest corneal thickness. A-CXL was non-inferior to S-CXL at three years in terms of best-corrected and uncorrected visual acuity, thinnest pachymetry, and astigmatism. For Kmax, non-inferiority could not be concluded.</pubmed_abstract><journal>Eye (London, England)</journal><pagination>1219-1224</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10102302</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Three-year follow-up of accelerated versus standard corneal cross-linking in paediatric Keratoconus.</pubmed_title><pmcid>PMC10102302</pmcid><pubmed_authors>Knyazer B</pubmed_authors><pubmed_authors>Hecht I</pubmed_authors><pubmed_authors>Dubinsky-Pertzov B</pubmed_authors><pubmed_authors>Einan-Lifshitz A</pubmed_authors><pubmed_authors>Achiron A</pubmed_authors><pubmed_authors>Hed S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Three-year follow-up of accelerated versus standard corneal cross-linking in paediatric Keratoconus.</name><description>&lt;h4>Purpose&lt;/h4>Standard corneal collagen cross-linking (S-CXL) is an effective treatment to arrest Keratoconus (KC) progression in children. Less is known on the long-term efficacy of accelerated CXL (A-CXL) in paediatric populations.&lt;h4>Methods&lt;/h4>A historical cohort analysis of paediatric patients (≤18 years) with KC who underwent S-CXL and A-CXL at two tertiary referral centres in Israel between 2010-2017. Preoperative and 3-year postoperative evaluation included changes in visual acuity (best spectacle corrected [BSCVA]) and uncorrected [UCVA]), refractive errors, and keratometric data.&lt;h4>Results&lt;/h4>Ninety-three eyes of 93 patients were analysed (A-CXL: n = 39; S-CXL: n = 54). Baseline characteristics were similar between groups. Both groups showed a significant improvement in visual acuity compared to baseline (S-CXL: 0.810-0.602 LogMAR UCVA; A-CXL: 0.890-0.306 LogMAR UCVA, p &lt; 0.05 for both). Improvement in BSCVA and UCVA following A-CXL was non-inferior to S-CXL (&lt; ± 0.2 LogMAR). Kmax decreased by a mean of 0.98 ± 5.56 dioptres following S-CXL (p = 0.02) and by 1.48 ± 8.4 dioptres following A-CXL (p = 0.015). Thinnest pachymetry decreased following both treatments (S-CXL: by 26.8 ± 40.7 µm, p = 0.001, A-CXL: by 10.2 ± 13.4 µm, p = 0.028), the difference between groups was within the non-inferiority margin (&lt; ± 10 µm).&lt;h4>Conclusions&lt;/h4>Paediatric patients followed for three years after A-CXL showed improved visual function, reduced corneal astigmatism and Kmax, and decreased thinnest corneal thickness. A-CXL was non-inferior to S-CXL at three years in terms of best-corrected and uncorrected visual acuity, thinnest pachymetry, and astigmatism. For Kmax, non-inferiority could not be concluded.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Apr</publication><modification>2025-04-04T19:58:53.665Z</modification><creation>2025-04-04T19:58:53.665Z</creation></dates><accession>S-EPMC10102302</accession><cross_references><pubmed>35590103</pubmed><doi>10.1038/s41433-022-02093-4</doi></cross_references></HashMap>